Key facts
- It has raised $90.0M.
- Notable investors include Evolution VC Partners, Catalio Capital Management, AbbVie Ventures, Eli Lilly, Innoviva — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Syndeio Biosciences
- ·The full record, as it builds
Funding rounds
No funding rounds for Syndeio Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Syndeio Biosciences
Operator of a synapse-focused biotech company intended to pioneer a new class of therapies for neuropsychiatric and cognitive disorders. The company offers therapies by harnessing event-driven pharmacology, a mechanism where a single drug dose triggers lasting biological changes that strengthen the connection between neurons, leveraging its innovative Boost Platform, spun out of Nobel Laureate Dr. Thomas Sudhof's lab at Stanford, to discover and pharmacologically characterize novel synapse drug targets for more effective strengthening of neuronal connections, enabling customers to develop transformative therapies by leveraging faster, safer and more effective mechanisms to strengthen synapses.
- Sector
- Healthcare
- HQ
- Indianapolis, IN, United States
- Founded
- 2025
- Employees
- 22
- Website
- syndeio.bio/
- Ownership
- Privately Held (backing)
Syndeio Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Syndeio Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Syndeio Biosciences in its N-PORT filings yet. We sweep new filings monthly.